VYNE Therapeutics Q2 EPS $(3.09) Misses $(1.99) Estimate, Sales $135.00K Beat $100.00K Estimate
Portfolio Pulse from Happy Mohamed
VYNE Therapeutics reported Q2 losses of $(3.09) per share, missing the analyst consensus estimate of $(1.99) by 55.28 percent. This is a 32.05 percent decrease from the same period last year. However, the company's quarterly sales of $135.00 thousand beat the analyst consensus estimate of $100.00 thousand by 35.00 percent, a 7.14 percent increase from last year.
August 14, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
VYNE Therapeutics reported a larger than expected Q2 loss but beat sales estimates. This mixed result could lead to uncertainty in the market.
VYNE Therapeutics reported a larger than expected loss for Q2, which is a negative signal for investors. However, the company beat sales estimates, which is a positive signal. The mixed results could lead to uncertainty in the market, potentially impacting the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100